Hyderabad-based Laurus Labs has been levelling up rapidly, having posted a 70% rise in consolidated revenue in FY21. The integrated pharmaceutical and biotech company manufactures active pharmaceutical ingredients (APIs) for select generic drugs used in antiAIDS, Hepatitis C and oncology therapy.
“We are thankful to the Economic Times for recognising Laurus Labs as the Emerging Company of the Year 2021,” chief executive Chava told ET.
“This recognition is the culmination of our efforts to create a sustainable organisation and the credit goes to all our team members working at Laurus Labs.”
Laurus has also been making important investments in the formulations business as it strives to become a fully integrated pharmaceutical company. The company currently earns two-thirds of its revenues from the API business.
The management plans to reduce the segment’s contribution to about 33% by FY25. The business still invests only 4% of its revenue toward research and development — a key element of growth for a drug supplier, although FY21 was an exceptional year of growth.
ET emerging co of the year: Laurus labs
